Figure 5From: Single low-dose rHuIL-12 safely triggers multilineage hematopoietic and immune-mediated effects Effect of rHuIL-12 or Placebo on EPO, IL-18 and CXCL10 levels in the Phase 1b expansion study. EPO, IL-18, and CXCL10 were measured at the indicated time points using validated assays. The mean changes from baseline after treatment with rHuIL-12 (12 μg) or placebo are shown as follows: A) EPO; B) IL-18; C) CXCL10.Back to article page